The safety and efficacy of Vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding Long-term results from a multicenter study

Medicine and Dentistry

• Vitamin K Antagonist 100%
• Patient 60%
• Combination Therapy 40%
• Atrial Fibrillation 40%
• Peptic Ulcer Bleeding 40%
• Major Adverse Cardiac Event 30%
• Major Bleeding 30%
• Therapeutic Procedure 30%
• Gastrointestinal Bleeding 20%
• Inpatient 20%
• Venous Ulcer 10%
• Analysis 10%
• Incidence 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Antivitamin K 100%
• Atrial Fibrillation 40%
• Peptic Ulcer Bleeding 40%
• Major Adverse Cardiac Event 30%
• Gastrointestinal Hemorrhage 20%
• Ulcer 10%
• Incidence 10%